COVID-19 -- Thailand
But uptake by patients and physicians has been low in the United States, where some therapies have been authorized for months.
Two clinical trials suggest that specific antibody treatments can prevent deaths and hospitalizations among people with mild or moderate COVID-19 -- particularly those who are at high risk of developing severe disease.
One study found that an antibody against the coronavirus developed by Vir Biotechnology in San Francisco, California, and GSK, headquartered in
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8250009&promed&0
No comments:
Post a Comment